Efficacy and Safety of Camrelizumab in Real-World Prospective Study

Sponsor
Guangdong Association of Clinical Trials
Study ID
NCT04793139
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.

Study Details

This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.

Key Dates

Start date
Apr 1, 2021
Status verified
Mar 2021
Primary completion
Jun 30, 2024
Completion
Dec 30, 2024

Study Design

Enrollment
1,000 participants (estimated)

Primary Outcome Measure

AE,Grade 3-5 [ Time Frame: From April 1, 2021 to Septeember 30, 2024 ]

Central Contacts

Related Studies